Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban

Thrombosis and Haemostasis

Volumn 111, Issue 5, 2014, Pages 989-995

  Herrmann, Richard ^a,b   Thom, James ^b   Wood, Alicia ^b   Phillips, Michael ^c   Muhammad, Shoaib ^b   Baker, Ross ^b,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d MURDOCH UNIVERSITY   (Australia)

Author keywords

Anticoagulants; Dabigatran; Reversal; Rivaroxaban; Thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; MORPHOLINE DERIVATIVE; PROTHROMBIN COMPLEX CONCENTRATES; THIOPHENE DERIVATIVE; THROMBIN;

ARTICLE; CALIBRATED AUTOMATED THROMBINOSCOPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG REVERSAL; HEART ATRIUM FIBRILLATION; HEMATOLOGICAL PROCEDURE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOELASTOGRAPHY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; COMPLICATION; DEVICES; HEMORRHAGE; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; LABORATORY AUTOMATION; METABOLISM; POSTOPERATIVE COMPLICATIONS; PROCEDURES; STROKE; TREATMENT WITHDRAWAL; VENOUS THROMBOSIS;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ATRIAL FIBRILLATION; AUTOMATION, LABORATORY; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; EQUIPMENT AND SUPPLIES; FACTOR VII; HEMORRHAGE; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; STROKE; THIOPHENES; THROMBELASTOGRAPHY; THROMBIN; THROMBIN TIME; VENOUS THROMBOSIS; WITHHOLDING TREATMENT;

EID: 84899721137     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0607     Document Type: Article

References (20)

1. Dahl OE, Huisman MV. Dabigatran etexilate: advances in anticoagulation therapy. Expert Rev Cardiovasc Ther 2010; 8: 771-774.
2. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
3. Gassanov N, Caglayan E, Er F. Apixaban: pharmacology and action profile. Dtsch Med Wochenschr 2012; 137: 138-141.
4. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
5. Avecilla ST, Ferrell C, Chandler WL, et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012; 137: 572-574.
6. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
7. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochemia medica: casopis Hrvatskoga drustva medicinskih biokemicara / HDMB 2012; 22: 329-341.
8. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
9. van Veen JJ, Smith J, Kitchen S, et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 2013; 160: 859-861.
10. Samama MM, Contant G, Spiro TE, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150-158.
11. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
12. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889-903.
13. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-162.
14. Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012; 50: 1799-1807.
15. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
16. Keeling D, Cotter F. Management of bleeding in patients taking FXa and FIIa inhibitors. Br J Haematol 2013; 160: 1-2.
17. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
18. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
19. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
20. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013; 35: 391-398.